EOLS
Price
$7.66
Change
+$0.15 (+2.00%)
Updated
Sep 5 closing price
Capitalization
495.49M
66 days until earnings call
TAK
Price
$15.40
Change
+$0.11 (+0.72%)
Updated
Sep 5 closing price
Capitalization
48.8B
54 days until earnings call
Interact to see
Advertisement

EOLS vs TAK

Header iconEOLS vs TAK Comparison
Open Charts EOLS vs TAKBanner chart's image
Evolus
Price$7.66
Change+$0.15 (+2.00%)
Volume$535K
Capitalization495.49M
Takeda Pharmaceutical
Price$15.40
Change+$0.11 (+0.72%)
Volume$3.33M
Capitalization48.8B
EOLS vs TAK Comparison Chart in %
Loading...
EOLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TAK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EOLS vs. TAK commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EOLS is a StrongBuy and TAK is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (EOLS: $7.66 vs. TAK: $15.40)
Brand notoriety: EOLS and TAK are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: EOLS: 37% vs. TAK: 86%
Market capitalization -- EOLS: $495.49M vs. TAK: $48.8B
EOLS [@Pharmaceuticals: Generic] is valued at $495.49M. TAK’s [@Pharmaceuticals: Generic] market capitalization is $48.8B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $67.95B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.93B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EOLS’s FA Score shows that 0 FA rating(s) are green whileTAK’s FA Score has 2 green FA rating(s).

  • EOLS’s FA Score: 0 green, 5 red.
  • TAK’s FA Score: 2 green, 3 red.
According to our system of comparison, TAK is a better buy in the long-term than EOLS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EOLS’s TA Score shows that 5 TA indicator(s) are bullish while TAK’s TA Score has 7 bullish TA indicator(s).

  • EOLS’s TA Score: 5 bullish, 2 bearish.
  • TAK’s TA Score: 7 bullish, 3 bearish.
According to our system of comparison, EOLS is a better buy in the short-term than TAK.

Price Growth

EOLS (@Pharmaceuticals: Generic) experienced а +0.39% price change this week, while TAK (@Pharmaceuticals: Generic) price change was +2.74% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +0.08%. For the same industry, the average monthly price growth was +12.00%, and the average quarterly price growth was +86.48%.

Reported Earning Dates

EOLS is expected to report earnings on Nov 11, 2025.

TAK is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+0.08% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TAK($48.8B) has a higher market cap than EOLS($495M). TAK YTD gains are higher at: 16.314 vs. EOLS (-30.616). TAK has higher annual earnings (EBITDA): 1.13T vs. EOLS (-33.58M). TAK has more cash in the bank: 419B vs. EOLS (61.7M). EOLS has less debt than TAK: EOLS (155M) vs TAK (4.51T). TAK has higher revenues than EOLS: TAK (4.48T) vs EOLS (278M).
EOLSTAKEOLS / TAK
Capitalization495M48.8B1%
EBITDA-33.58M1.13T-0%
Gain YTD-30.61616.314-188%
P/E RatioN/A53.30-
Revenue278M4.48T0%
Total Cash61.7M419B0%
Total Debt155M4.51T0%
FUNDAMENTALS RATINGS
EOLS vs TAK: Fundamental Ratings
EOLS
TAK
OUTLOOK RATING
1..100
5226
VALUATION
overvalued / fair valued / undervalued
1..100
92
Overvalued
6
Undervalued
PROFIT vs RISK RATING
1..100
7395
SMR RATING
1..100
10089
PRICE GROWTH RATING
1..100
9153
P/E GROWTH RATING
1..100
10033
SEASONALITY SCORE
1..100
1065

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TAK's Valuation (6) in the Pharmaceuticals Major industry is significantly better than the same rating for EOLS (92). This means that TAK’s stock grew significantly faster than EOLS’s over the last 12 months.

EOLS's Profit vs Risk Rating (73) in the Pharmaceuticals Major industry is in the same range as TAK (95). This means that EOLS’s stock grew similarly to TAK’s over the last 12 months.

TAK's SMR Rating (89) in the Pharmaceuticals Major industry is in the same range as EOLS (100). This means that TAK’s stock grew similarly to EOLS’s over the last 12 months.

TAK's Price Growth Rating (53) in the Pharmaceuticals Major industry is somewhat better than the same rating for EOLS (91). This means that TAK’s stock grew somewhat faster than EOLS’s over the last 12 months.

TAK's P/E Growth Rating (33) in the Pharmaceuticals Major industry is significantly better than the same rating for EOLS (100). This means that TAK’s stock grew significantly faster than EOLS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EOLSTAK
RSI
ODDS (%)
Bullish Trend 1 day ago
83%
Bearish Trend 1 day ago
57%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
75%
Bullish Trend 1 day ago
43%
Momentum
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
32%
MACD
ODDS (%)
Bullish Trend 1 day ago
74%
Bullish Trend 1 day ago
46%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
40%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
82%
Bullish Trend 1 day ago
36%
Advances
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
42%
Declines
ODDS (%)
Bearish Trend 4 days ago
81%
Bearish Trend 11 days ago
45%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
88%
Bearish Trend 1 day ago
50%
Aroon
ODDS (%)
N/A
Bullish Trend 1 day ago
36%
View a ticker or compare two or three
Interact to see
Advertisement
EOLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TAK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JATTX27.380.16
+0.59%
Janus Henderson Triton T
ASQGX17.84N/A
N/A
American Century Small Company R5
MAMEX22.01N/A
N/A
MoA Mid Cap Equity Index Fund
SROIX13.63N/A
N/A
Calamos Antetokounmpo Sustainable Eqs I
MSOIX40.10-0.11
-0.27%
NYLI WMC Enduring Capital Class I

EOLS and

Correlation & Price change

A.I.dvisor indicates that over the last year, EOLS has been loosely correlated with PRGO. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if EOLS jumps, then PRGO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EOLS
1D Price
Change %
EOLS100%
+2.00%
PRGO - EOLS
43%
Loosely correlated
-2.75%
AMRX - EOLS
33%
Poorly correlated
+0.73%
LNTH - EOLS
32%
Poorly correlated
+1.73%
ALKS - EOLS
30%
Poorly correlated
+3.53%
CRDL - EOLS
30%
Poorly correlated
-1.80%
More

TAK and

Correlation & Price change

A.I.dvisor indicates that over the last year, TAK has been loosely correlated with HLN. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if TAK jumps, then HLN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TAK
1D Price
Change %
TAK100%
+0.72%
HLN - TAK
43%
Loosely correlated
-0.41%
ZTS - TAK
29%
Poorly correlated
+0.08%
EOLS - TAK
24%
Poorly correlated
+2.00%
RDY - TAK
23%
Poorly correlated
+1.34%
DVAX - TAK
23%
Poorly correlated
+0.80%
More